Many studies have confirmed the activity of thalidomide in MM, as well as an improved response with dexamethasone. Newer thalidomide derivatives with reduced toxicity (neuropathy, teratogenicity) are also promising. Thalidomide with dexamethasone may now represent the treatment of choice for previously untreated patients. Further studies with these and other novel agents early in the course of myeloma may improve complete remission rates and frequency of long-term control.
Michèle Cavo, S. Vincent Rajkumar, Antonio Palumbo, Philippe Moreau, Robert Z. Orlowski, Joan Bladé, Orhan Sezer, Heinz Ludwig, Meletios A Dimopoulos, Michel Attal, Pieter Sonneveld, Mario Boccadoro, Kenneth C. Anderson, Paul G. Richardson, William Bensinger, Hans Erik Johnsen, Nicolaus Kroeger, Gösta Gahrton, P. Leif Bergsagel, David H. Vesole, Hermann Einsele, ,
Heinz Ludwig, Meral Beksaç, Joan Bladé, Mario Boccadoro, Jamie Cavenagh, Michèle Cavo, Meletios A Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Façon, Hartmut Goldschmidt, Jean‐Luc Harousseau, U Hess, Nicolas Ketterer, Martin Kropff, Л. П. Менделеева, Gareth J. Morgan, Antonio Palumbo, Torben Plesner, Jesús F. San Miguel, Ofer Shpilberg, Pia Sondergeld, Pieter Sonneveld, Sonja Zweegman
Discussion(0)
No comments yet. Be the first to comment.